ES2153964T3 - Liberacion controlada de farmacos administrados por via sublingual o bucal. - Google Patents

Liberacion controlada de farmacos administrados por via sublingual o bucal.

Info

Publication number
ES2153964T3
ES2153964T3 ES96919399T ES96919399T ES2153964T3 ES 2153964 T3 ES2153964 T3 ES 2153964T3 ES 96919399 T ES96919399 T ES 96919399T ES 96919399 T ES96919399 T ES 96919399T ES 2153964 T3 ES2153964 T3 ES 2153964T3
Authority
ES
Spain
Prior art keywords
sublingual
oral
road
controlled release
drugs administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96919399T
Other languages
English (en)
Inventor
Ragab El-Rashidy
Bruce Ronsen
Emad Eldin Hassan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pentech Pharmaceuticals Inc
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2153964T3 publication Critical patent/ES2153964T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

UNA COMPOSICION QUE PROPORCIONA UNA LIBERACION RELATIVAMENTE LENTA DE FARMACOS HIDROSOLUBLES, TALES COMO LA APOMORFINA, PARA SU ADMINISTRACION POR VIA SUBLINGUAL O BUCAL.
ES96919399T 1995-06-13 1996-06-13 Liberacion controlada de farmacos administrados por via sublingual o bucal. Expired - Lifetime ES2153964T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/489,966 US5624677A (en) 1995-06-13 1995-06-13 Controlled release of drugs delivered by sublingual or buccal administration

Publications (1)

Publication Number Publication Date
ES2153964T3 true ES2153964T3 (es) 2001-03-16

Family

ID=23946020

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96919399T Expired - Lifetime ES2153964T3 (es) 1995-06-13 1996-06-13 Liberacion controlada de farmacos administrados por via sublingual o bucal.

Country Status (10)

Country Link
US (1) US5624677A (es)
EP (1) EP0833619B1 (es)
AT (1) ATE198269T1 (es)
AU (1) AU705488B2 (es)
DE (1) DE69611369T2 (es)
DK (1) DK0833619T3 (es)
ES (1) ES2153964T3 (es)
GR (1) GR3035548T3 (es)
PT (1) PT833619E (es)
WO (1) WO1996041619A1 (es)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9700878D0 (en) * 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
IN186245B (es) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6495539B1 (en) 1998-02-19 2002-12-17 Washington University B-lactam-like chaperone inhibitors
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US6011035A (en) 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
JP2002539165A (ja) * 1999-03-16 2002-11-19 ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド 舌下またはバッカル投与により送出されるシルデナフィルの制御放出
PL211402B1 (pl) * 1999-09-03 2012-05-31 Apbi Holdings Zastosowanie dapoksetyny do leczenia lub zwalczania przedwczesnej ejakulacji
US6841559B1 (en) 1999-11-19 2005-01-11 Washington University Of St. Louis Pyridinones to treat and prevent bacterial infections
US6506765B2 (en) 2000-04-07 2003-01-14 Tap Pharmaceutical Products, Inc. Apomorphine derivatives and methods for their use
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
EP1365740A1 (en) * 2001-02-08 2003-12-03 Pharmacia Corporation Rapid-onset medicament for the treatment of sexual dysfunction
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US20060073174A1 (en) * 2001-08-16 2006-04-06 Access Pharmaceuticals, Inc. Adherent and erodible film to treat a moist surface of a body tissue
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
DK1471890T3 (da) * 2002-02-07 2007-01-08 Pharmacia Corp Farmaceutisk doseringsform til mukös afgivelse
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7507760B2 (en) * 2004-01-22 2009-03-24 Neuromed Pharmaceuticals Ltd. N-type calcium channel blockers
WO2005102330A2 (en) * 2004-04-16 2005-11-03 Washingtion University Amino methylated 2-pyridinones
MX2007002783A (es) * 2004-09-09 2009-02-12 Bayer Animal Health Gmbh Composición farmacéutica.
US20070020186A1 (en) * 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
JP2009504803A (ja) * 2005-08-22 2009-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒアゴニスト
US9265732B2 (en) 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
CA2643924A1 (en) * 2006-04-17 2007-10-25 Neuromed Pharmaceuticals Ltd. Isoxazole derivatives as calcium channel blockers
EP2029597A4 (en) 2006-05-31 2011-11-23 Univ California purine analogs
US7956064B2 (en) 2006-09-01 2011-06-07 Cylene Pharmaceuticals, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
EP2061780A4 (en) * 2006-09-14 2010-12-22 Zalicus Pharmaceuticals Ltd DIARYLE PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS
EP2074105A4 (en) * 2006-10-13 2010-10-06 Neuromed Pharmaceuticals Ltd CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM INHIBITORS
US20090054333A1 (en) * 2006-10-17 2009-02-26 Antonio Giordano Peptide inhibitors of cyclin-dependent kinase activity and uses thereof
ES2456964T3 (es) 2007-02-07 2014-04-24 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
WO2008128121A1 (en) * 2007-04-12 2008-10-23 Joyant Pharmaceuticals, Inc. Smac mimetic dimers and trimers useful as anti-cancer agents
CN101801190A (zh) * 2007-06-22 2010-08-11 赛林药物股份有限公司 治疗异常细胞增殖性疾病的方法
WO2009002838A1 (en) * 2007-06-22 2008-12-31 Cylene Pharmaceuticals, Inc. Methods for treating ophthalmic disorders
US7910600B2 (en) * 2007-08-31 2011-03-22 Cylene Pharmaceuticals, Inc. Therapeutic kinase modulators
CA2705761C (en) 2007-11-14 2016-04-26 Kereos, Inc. Super-oxide dismutase mimetics
US20090155392A1 (en) * 2007-12-17 2009-06-18 Bret David Nelson Methods and Systems for Sublingual Guarana Administration
WO2009086170A1 (en) * 2007-12-21 2009-07-09 Joyant Pharmaceuticals, Inc. Diazonamide analogs with improved solubility
JP2011511073A (ja) * 2008-02-07 2011-04-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒ７活性化物質による膀胱の疾患の治療
CN102036561A (zh) * 2008-02-29 2011-04-27 赛林药物股份有限公司 蛋白激酶调节剂
WO2009132454A1 (en) * 2008-04-28 2009-11-05 Neuromed Pharmaceuticals Ltd. Di-t-butylphenyl piperazines as calcium channel blockers
CA2722704A1 (en) * 2008-04-28 2009-11-05 Zalicus Pharmaceuticals Ltd. Cyclylamine derivatives as calcium channel blockers
WO2009132452A1 (en) * 2008-04-28 2009-11-05 Neuromed Pharmaceuticals Ltd. Diaryl-cyclylalkyl derivatives as calcium channel blockers
JP5123429B2 (ja) * 2008-04-29 2013-01-23 ジョイアント ファーマスーティカルズ、インク． インドリン抗癌剤
WO2009143485A1 (en) * 2008-05-22 2009-11-26 Joyant Pharmaceuticals, Inc. Diazonamide analogs
US8377968B2 (en) 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
WO2010093436A2 (en) 2009-02-11 2010-08-19 Carson Dennis A Toll-like receptor modulators and treatment of diseases
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
MX2012002426A (es) 2009-08-26 2012-06-27 Cylene Pharmaceuticals Inc Quinolinas condensadas como moduladores de proteina cinasa.
CA2789879A1 (en) 2009-10-28 2011-05-19 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
WO2011064316A2 (en) 2009-11-25 2011-06-03 Paolo Botti Mucosal delivery of peptides
RU2607453C2 (ru) 2009-12-04 2017-01-10 Сенхва Байосайенсиз, Инк. Пиразолопиримидины и родственные гетероциклы как ск2 ингибиторы
EP2563401A1 (en) 2010-04-30 2013-03-06 Telormedix SA Methods for inducing an immune response
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
WO2011134668A1 (en) 2010-04-30 2011-11-03 Telormedix Sa Phospholipid drug analogs
BR112013000776A2 (pt) 2010-07-13 2016-05-24 Ultragenyx Pharmaceutical Inc método e formulação para tratamento de deficiência de ácido siálico
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators
KR20140021520A (ko) 2010-10-22 2014-02-20 위니베르시떼 드 스트라스부르 Hsp90 관련 질환의 치료에 유용한 포코옥심 컨쥬게이트
EP2651357B1 (en) 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublingual films
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
EP2654726A1 (en) * 2011-03-08 2013-10-30 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
ES2652444T3 (es) 2011-04-22 2018-02-02 Joyant Pharmaceuticals, Inc. Análogos de diazonamida
WO2013063149A1 (en) 2011-10-24 2013-05-02 Ultragenyx Pharmaceutical, Inc. Sialic acid analogs
EP2903987B1 (en) 2012-10-01 2017-09-20 Urogen Pharma Ltd. Phospholipid drug analogs
WO2014186410A1 (en) 2013-05-13 2014-11-20 NeuOra Microceuticals, LLC Long lasting breath mint
JP2016535794A (ja) 2013-11-11 2016-11-17 インパックス ラボラトリーズ，インコーポレーテッド 急速崩壊性製剤及びその使用法
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
CN107205940A (zh) 2014-12-15 2017-09-26 约翰霍普金斯大学 舒尼替尼制剂及其在治疗眼部疾病中的使用方法
EP4289950A3 (en) 2015-01-09 2024-01-24 Revolution Medicines, Inc. Macrocyclic compounds that participate in cooperative binding and medical uses thereof
TW201629069A (zh) 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
EP4578461A3 (en) 2015-04-21 2025-09-03 Sumitomo Pharma America, Inc. Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
WO2017048817A1 (en) 2015-09-14 2017-03-23 Ultragenyx Pharmaceutical Inc. Crystal forms of sialic acid or salt or solvate thereof
EP3355930A4 (en) 2015-10-01 2019-03-06 Warp Drive Bio, Inc. METHOD AND REAGENTS FOR THE ANALYSIS OF PROTEIN-PROTEIN INTERFACES
HK1257499A1 (zh) 2015-11-12 2019-10-25 Graybug Vision, Inc. 用於治疗的聚集性微粒
US20190144503A1 (en) 2016-04-27 2019-05-16 Regents Of The University Of Minnesota Methods for the identification of bifunctional compounds
CN109414454A (zh) 2016-05-03 2019-03-01 加莱拉实验室有限责任公司 用于癌症治疗的组合疗法
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
US11517545B2 (en) 2016-12-15 2022-12-06 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
AU2018240462C1 (en) 2017-03-23 2022-12-08 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
US11912706B2 (en) 2017-03-28 2024-02-27 Pimera, Inc. Crystal forms of a POL1 inhibitor
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
EP3728189A1 (en) 2017-12-20 2020-10-28 Bellicum Pharmaceuticals, Inc. Multimeric piperidine derivatives
US11766432B2 (en) * 2018-07-27 2023-09-26 Serina Therapeutics, Inc. Cleavable conjugates of catechol compounds and water-soluble polymers and methods of treatment using the same
EP3996746A4 (en) 2019-07-11 2023-08-23 Praxis Precision Medicines, Inc. T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF
CN114786777A (zh) 2019-11-04 2022-07-22 锐新医药公司 Ras抑制剂
CN114867735A (zh) 2019-11-04 2022-08-05 锐新医药公司 Ras抑制剂
PE20221277A1 (es) 2019-11-04 2022-09-05 Revolution Medicines Inc Inhibidores de ras
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
KR20230042600A (ko) 2020-06-18 2023-03-28 레볼루션 메디슨즈, 인크. Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
AU2021345111B2 (en) 2020-09-15 2025-11-27 Revolution Medicines, Inc. Indole derivatives as Ras inhibitors in the treatment of cancer
AR125782A1 (es) 2021-05-05 2023-08-16 Revolution Medicines Inc Inhibidores de ras
EP4334324A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CR20230558A (es) 2021-05-05 2024-01-24 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cáncer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
AU2023285116A1 (en) 2022-06-10 2024-12-19 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN120659773A (zh) 2022-11-09 2025-09-16 锐新医药公司 化合物、复合物以及其制备方法和用途
WO2024186579A1 (en) 2023-03-03 2024-09-12 Deliver Therapeutics, Inc. Protein kinase inhibitors and uses thereof
WO2024186580A1 (en) 2023-03-03 2024-09-12 Deliver Therapeutics, Inc. Protein kinase inhibitors and uses thereof
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
EP4688790A1 (en) 2023-04-07 2026-02-11 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025213185A1 (en) 2024-04-05 2025-10-09 Revolution Medicines, Inc. Peptide conjugates
WO2025213065A1 (en) 2024-04-05 2025-10-09 Revolution Medicines, Inc. Peptide conjugates
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US3428728A (en) * 1965-10-21 1969-02-18 Hans Lowey Timed release sublingual medications
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
DE3338978A1 (de) * 1982-10-29 1984-05-03 Basf Ag, 6700 Ludwigshafen Verapamil und gallopamil und ihre physiologisch vertraeglichen salze zur resorptiven anwendung auf den schleimhaeuten des mundes, des nasen-rachen-raums und des rektums
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
CA2188385C (en) * 1994-04-22 2000-07-11 Ragab El-Rashidy Dosage forms and method for ameliorating male erectile dysfunction

Also Published As

Publication number Publication date
DE69611369T2 (de) 2001-04-26
DK0833619T3 (da) 2001-01-22
WO1996041619A1 (en) 1996-12-27
DE69611369D1 (de) 2001-02-01
US5624677A (en) 1997-04-29
ATE198269T1 (de) 2001-01-15
EP0833619A4 (en) 1998-12-30
EP0833619A1 (en) 1998-04-08
EP0833619B1 (en) 2000-12-27
GR3035548T3 (en) 2001-06-29
AU705488B2 (en) 1999-05-20
PT833619E (pt) 2001-04-30
AU6174996A (en) 1997-01-09

Similar Documents

Publication Publication Date Title
GR3035548T3 (en) Controlled release of drugs delivered by sublingual or buccal administration
TW430562B (en) Controlled release of drugs delivered by sublingual or buccal administration
NZ527867A (en) Oral pharmaceutical composition of cefpodoxime proxetil
BG104315A (en) Prostaglandine agonists and their application for the treatment of osteal diseases
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
BR9916835A (pt) Composição de galantamina de liberação controlada
ES2176296T3 (es) Composiciones farmaceuticas que permiten la liberacion prolongada de trimetacidina despues de la administracion por via oral.
NO963673L (no) Orale vehikkelblandinger
SE9704546D0 (sv) Novel compounds
IL117091A0 (en) Methylphenyloxazolidinone derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
DK0717041T3 (da) Krystallinske paclitaxel-hydrater
BRPI0408895A (pt) formulações de cladribina para administração oral e transmucosal aperfeiçoada
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
MY143221A (en) Orodispersible pharmaceutical composition for oromucosal or sublingual administration of agomelatine
BR0212931A (pt) Composição farmacêutica de liberação prolongada contendo metformina
ES2159362T3 (es) Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
BR0207066A (pt) Derivados do 2h-1-benzopirano - processos para sua preparação e composições farmacêuticas a partir deles
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
AP2001002369A0 (en) Pharmaceutical complex.
DE69802943D1 (de) Arzneizubereitung zur verabreichung von thiocolchicosid durch die mundschleimhaut
PT1052995E (pt) Composicao farmaceutica para a administracao por via nasal de tiocolchicosido
UY26746A1 (es) Liberación controlada de fármacos administrados por via sublingual o bucal
AR023056A1 (es) Composiciones farmaceuticas basadas en alfa-ciclodextrina para la administracion por via oral de analogos de lh-rh

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 833619

Country of ref document: ES